Selventa Developing Powerful New Class of Multi-omic Based Diagnostic Test for Autoimmune Disease and Cancer

Selventa Developing Powerful New Class of Multi-omic Based Diagnostic Test for Autoimmune Disease and Cancer

January 22, 2013
Cambridge, Mass., January 22, 2013 - Selventa today announced that it is developing a powerful new class of diagnostic test that will accelerate the implementation of personalized healthcare. Systems Diagnostics, or SysDx™, will be a novel diagnostic tests that can consist of “multi-omic” biomarkersselected through a rigorous Big Data analysis of a patient’s biological profile includinggenomic, epigenomic, transcriptomic, proteomic, metabolomic and electronic medial record information.

Moderna Appoints Divakar Ramakrishnan, Ph.D., As Senior Vice President Of Process Development, Manufacturing And Quality

Moderna Appoints Divakar Ramakrishnan, Ph.D., As Senior Vice President Of Process Development, Manufacturing And Quality

January 16, 2013

CAMBRIDGE, Mass., Jan. 16, 2013 /PRNewswire/ -- Moderna Therapeutics, which is developing a new platform designed to spur the body to create its own therapeutic proteins to treat a wide range of diseases, announced today that Divakar Ramakrishnan, Ph.D., is joining the company as Senior Vice President of Process Development, Manufacturing and Quality. His appointment is effective immediately.

BIND Granted 5 US Patents for Medicinal Nanoengineering® Platform & Lead Drug Candidate, BIND-014

BIND Granted 5 US Patents for Medicinal Nanoengineering® Platform & Lead Drug Candidate, BIND-014

January 8, 2013

Total of Ten U.S. Patents Issued to Company in 2012

BIND and Amgen Sign Development & Commercialization Agreement for Kinase Inhibitor Nanomedicine

BIND and Amgen Sign Development & Commercialization Agreement for Kinase Inhibitor Nanomedicine

January 8, 2013

BIND Biosciences and Amgen Sign Agreement for the Worldwide Development and Commercialization of a Kinase Inhibitor Nanomedicine

Collaboration to Develop a Novel and Targeted Accurin™ Based on BIND’s Nanomedicine Platform and Amgen’s Kinase Inhibitor

Receptos Doses First Patient in Phase 2 Trial for RPC1063 in Ulcerative Colitis

Receptos Doses First Patient in Phase 2 Trial for RPC1063 in Ulcerative Colitis

January 4, 2013

SAN DIEGO, Jan. 4, 2013 /PRNewswire/ -- Receptos, Inc., announced today that its selective sphingosine-1- phosphate 1 receptor (S1P1R) modulator, RPC1063, has been administered to the first patient in a Phase 2 study examining the clinical efficacy and safety of induction therapy in patients with moderately to severely active ulcerative colitis (UC).

BG Medicine Announces Obtaining CE Mark and Launching of Automated BGM Galectin-3 Test

BG Medicine Announces Obtaining CE Mark and Launching of Automated BGM Galectin-3 Test

January 2, 2013

Moderna Therapeutics Announces Appointment Of Stephen Hoge, MD As Senior Vice President Of Corporate Development And New Drug Concepts

Moderna Therapeutics Announces Appointment Of Stephen Hoge, MD As Senior Vice President Of Corporate Development And New Drug Concepts

December 19, 2012

CAMBRIDGE, Mass., Dec. 19, 2012 /PRNewswire via COMTEX/ -- Moderna Therapeutics, which is developing a new platform designed to spur the body to create its own therapeutic proteins to treat a wide range of diseases, announced today that Stephen Hoge, MD, currently a partner at McKinsey & Company, will join the company as Senior Vice President of Corporate Development and New Drug Concepts on January 1st, 2013. In this newly created role, Dr.

Blend Therapeutics Appoints Mark Iwicki as Chief Executive Officer

Blend Therapeutics Appoints Mark Iwicki as Chief Executive Officer

December 18, 2012

Pharmaceutical industry leader to drive company growth and strategy with initial focus on new classes of cancer therapies

Blend Therapeutics Closes $16 Million in Series B Financing

Blend Therapeutics Closes $16 Million in Series B Financing

December 18, 2012

Company accelerates product development with two lead programs

BG Medicine Obtains CE Mark for CardioSCORE(TM) Test in Europe

BG Medicine Obtains CE Mark for CardioSCORE(TM) Test in Europe

December 11, 2012

Innovative Blood Test for the Prediction of Major Cardiovascular Events Expected to Launch in the First Half of 2013